Ivermectin effect in treatment of patients with human fascioliasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105291155N13

Enrollment

Registered

2011-06-18

Start date

2011-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasciola. Infection due to Fasciola

Interventions

Ivermectin effect in treatment of patients with Fascioliasis It's given appropriate dose Ivermectin 200 microgram per kg, ie 3 mg two tablets morning and night in one day to the patient..

Treatment - Drugs

Ivermectin effect in treatment of patients with Fascioliasis It's given appropriate dose Ivermectin 200 microgram per kg, ie 3 mg two tablets morning and night in one day to the patient.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: persons are over 18 years old with human fascioliasis Exclusion criteria: pregnancy;lactation;hypersensitivy to the drug

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ivermectin effect in treatment of patients with Fascioliasis. Timepoint: 1 month and 3 months after treatment. Method of measurement: negative ELISA- negative S/E-absence of hypereosinophilia-recovery of patients signs.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Joukar

gastrointestinal and liver disease research center (GLDRC)

f_jokar@gums.ac.ir+98 13 1553 5116

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026